NEW YORK — The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings.
Week of June 17.
Akero Therapeutics – San Francisco, 5 million shares, priced $14-$16, managed by JP Morgan/Jefferies. Proposed Nasdaq symbol AKRO. Business: Early stage biotech developing therapies for NASH and other metabolic diseases.
Atreca – Redwood City, Calif., 7.4 million shares, priced $16-$18, managed by Cowen/Evercore ISI. Proposed Nasdaq symbol BCEL. Business: Preclinical biotech developing immunotherapies for solid tumors.
Cambium Networks – Rolling Meadows, Ill., 5.8 million shares, priced $13-$15, managed by JP Morgan/Goldman Sachs. Proposed Nasdaq symbol CMBM. Business: Provides wireless broadband networking products.
Change Healthcare – Nashville, Tenn., 42.9 million shares, priced $16-$19, managed by Barclays Goldman Sachs. Proposed Nasdaq symbol CHNG. Business: Provides healthcare revenue cycle management software and services.
Dermavant Sciences – Phoenix, Ariz., 7.7 million shares, priced $12-$14, managed by Jefferies/SVB Leerink. Proposed Nasdaq symbol DRMT. Business: Phase 3 biotech developing in-licensed therapies for dermatological diseases.
G Medical Innovations – London, 1.4 million shares, priced at $10.50, managed by HC Wainwright. Proposed Nasdaq symbol GMVD. Business: Provides app-connected medical devices for monitoring vital signs.
Grocery Outlet Holdings – Emeryville, Calif., 17.2 million shares, priced $15-$17, managed by BofA Merrill Lynch/Morgan Stanley. Proposed Nasdaq symbol Go. Business: Operates a network of more than 300 independently run discount grocery stores.
Linx – Sao Paulo, Brazil, 29.3 million shares, priced at $8.68, managed by Goldman Sachs/Morgan Stanley. Proposed NYSE symbol LINX. Business: Brazilian provider of POS/ERP connectivity software and payment services.
Morphic Holding – Waltham, Mass., 5 million shares, priced $14-$16, managed by Jefferies/Cowen. Proposed Nasdaq symbol MORF. Business: Developing oral small-molecule integrin therapeutics for various chronic diseases.
Personalis – Menlo Park, Calif., 6.7 million shares, priced $14-$16, managed by Morgan Stanley/BofA Merrill Lynch. Proposed Nasdaq symbol PSNL. Business: Provides a genome sequencing platform for cancer drug development.
Pivotal Investment II – New York, 20 million shares, priced at $10, managed by Cantor Fitzgerald/BTIG. Proposed NYSE PIC.U. Business: Blank check company led by acquisition veteran Jonathan Ledecky targeting a high-growth business.
Prevail Therapeutics – New York, 7.4 million shares, priced $16-$18, managed by Morgan Stanley/BofA Merrill Lynch. Business: Early stage biotech developing gene therapies for neurodegenerative diseases.
Slack Technologies – San Francisco, 283.4 million shares, priced at $26.82, managed by Goldman Sachs/Morgan Stanley. Business: Provides a workplace messaging application.
Stoke Therapeutics – Bedford, Mass., 6.7 million shares, priced $14-$16, managed by JP Morgan/Cowen. Proposed Nasdaq symbol STOK. Business: Preclincial biotech developing RNA-targeted therapies for rare genetic diseases.
The Associated Press